Exane has been engaged to produce research on the Company. The intention is to raise the visibility of the Company and enable investors and stakeholders to develop an improved understanding of the business
*Important notice: Please refer to our complete disclosure notice and conflict of interest policy available on [http://cube.exane.com/compliance*]
This research is produced by one or more of EXANE SA (including Exane SA branches, based in the United Kingdom, in the European Economic Area and in Switzerland) and Exane Inc (collectively referred to as "EXANE").
EXANE SA is authorized by the Autorite de Controle Prudentiel et de Resolution and regulated by the Autorite des Marches Financiers ("AMF").
Exane SA branches based in the European Economic Area are authorized and regulated by ACPR and by the local relevant regulator.
Exane SA Geneva Branch is authorized and regulated by the Swiss Financial Market Supervisory Authority ("FINMA").
Exane SA, London Branch is deemed authorised and regulated by the Financial Conduct Authority.
Details of the Financial Services Contracts Regime, which allows EEA-based firms to operate in the UK for a limited period to carry on activities which are necessary for the performance of pre-existing contracts, are available on the Financial Conduct Authority's website.